About Bienta

Bienta is a trademark for preclinical biology services of Enamine, the world’s largest supplier of drug-like molecules for drug discovery research. Bienta is operating as a Contract Research Organisation (CRO) providing biomolecular screening (HTS) services as well as comprehensive bioanalytical support of drug discovery projects, including in vitro ADMET (absorption, distribution, metabolism, excretion, toxicity) testing as well as pharmacokinetics (PK) and toxicity studies in animals.

Time- and Cost-Effective Screening

Rapid direct access to the vast Enamine’s off-the shelf compound collection (Screening Collection) and Enamine’s explored virtual chemical space for drug-like structures (REAL Database™),  in combination with the powerful in-house chemoinformatics and molecular modeling, enables an exceptionally efficient iterative screening, making it possible to step forward from in silico screening sets to the lead generation stage in weeks.

High Throughput Screening & ADME-Tox Services

HTS Lab at Bienta is a well-equipped screening facility with a broad range of robotic liquid handling and signal readout technology capabilities as well as the capacity to run both biochemical and cell-based assays in 384-well plate format. Bioanalytical Lab is established to provide all common in vitro ADMET tests as well as analytical support of pharmacokinetics and animal tox services.

Discover your molecules with us

News & Events

BIENTA at 18th European Symposium on Fluorine Chemistry

Bienta will be paricipating in the 18th European Symposium on Fluorine Chemistry, Kyiv, Ukraine, August 7th–12th, 2016. N-arylsulfamoylbenzenesulfonyl fluorides as inhibitors of serine proteases Petro Borysko,1 Maria Kliachyna,1  Sergey Zozulya,1,2 Oleksandr Vasylchenko,3 Andrey Bogolubsky,1 Yurii Moroz,2 Pavel Mykhailiuk,1,4 and Andrey Tolmachev1,2 1Enamine Ltd., 78 Chervonotkatska Street, Kyiv, 02094, Ukraine, www.enamine.net. 2ChemBioCenter, Kyiv National Taras Shevchenko University, 61 Chervonotkatska Street, Kyiv,...

European Horizon 2020 project at Bienta

Enamine/Bienta is participating in EU Horizon 2020 grant-funded program“Peptidomimetics with photocontrolled biological activity” headed by research teams from Karlsruhe Institute of Technology, University of Cambridge, Latvian Institute of Organic Synthesis and Enamine. Bienta’s preclinical biology team is supporting characterization of a photodynamic cancer drug candidate by DMPK and animal efficacy studies. In April 2016, Bienta’s researchers co-authored a prestigious...

Metabolite identification

Knowing specific sites and pathways of metabolic transformations is useful for guiding synthetic optimization of lead compounds to overcome stability or toxicity issues commonly occurring in drug discovery. Over the last few years, Bienta’s ADME/mass-spectrometry team has accumulated substantial experience in running efficient and affordably priced Metabolite ID projects to help tackling the challenges of synthetic optimization for Enamine’s...

Read More